Antidepressant-like activity of (4-phenylpiperazin-1-yl) (quinoxalin-2-yl) methanone (4a), a novel 5-HT 3 receptor antagonist: An investigation in behaviour-based rodent models of depression

Indian Journal of Pharmacology

Volumn 44, Issue 5, 2012, Pages 560-565

  Mahesh, Radhakrishnan ^a   Kumar, Baldev ^a   Jindal, Ankur ^a   Bhatt, Shvetank ^a   Devadoss, Thangaraj ^a   Pandey, Dilip ^a  

^a BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

Author keywords

(4 phenylpiperazin 1 yl) (quinoxalin 2 yl) methanone; 4a; 5 HT 3 receptor antagonist; depression; forced swim test; olfactory bulbectomy

Indexed keywords

(4 PHENYLPIPERAZIN 1 YL) (QUINOXALIN 3 YL) METHANONE; 5 HYDROXYTRYPTOPHAN; ANTIDEPRESSANT AGENT; FLUOXETINE; PARGYLINE; RESERPINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE MODEL; FORCED SWIMMING TEST; HEAD TWITCH; HYPOTHERMIA; LOCOMOTION; MOUSE; NONHUMAN; OLFACTORY BULBECTOMY; OPEN FIELD BEHAVIOR; RAT;

(4-PHENYLPIPERAZIN-1-YL) (QUINOXALIN-2-YL) METHANONE; 4A; 5-HT3 RECEPTOR ANTAGONIST; DEPRESSION; FORCED SWIM TEST; OLFACTORY BULBECTOMY;

ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSION; DISEASE MODELS, ANIMAL; MALE; MICE; PIPERAZINES; RATS; RATS, WISTAR; SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS;

EID: 84866232916     PISSN: 02537613     EISSN: 19983751     Source Type: Journal    
DOI: 10.4103/0253-7613.100371     Document Type: Article

References (32)

1. Yi LT, Li JM, Li YC, Pan Y, Xu Q, Kong LD. Antidepressant-like behavioral and neurochemical effects of the citrus-associated chemical apigenin. Life Sci 2008;82:741-51.
2. Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM. Neurobiology of depression. Neuron 2002;34:13-25.
3. Berton O, Nestler EJ. New approaches to antidepressant drug discovery: Beyond monoamines. Nat Rev Neurosci 2006;7:137-51.
4. Adell A, Castro A, Celada P, Bortolozzi A, Pazos A, Artigas F. Strategies for producing faster acting antidepressants. Drug Discov Today 2005;10:578-85.
5. Mahesh R, Perumal RV, Pandi PV. Cancer chemotherapy induced nausea and vomiting: Role of mediators, development of drugs and treatment methods. Pharmazie 2005;60:83-96.
6. Wolf H. Preclinical and clinical pharmacology of the 5-HT3 receptor Antagonists. Scand J Rheumatol 2000;29:37-45.
7. Martin KF, Hannon S, Phillips I, Heal DJ. Opposing roles for 5-HT1B and 5-HT3 receptors in the control of 5-HT release in rat hippocampus in vivo. Br J Pharmacol 1992;106:139-42.
8. Mitchell EA, Pratt JA. Neuroanatomical structures involved in the action of the 5-HT3 antagonist ondansetron: A 2-deoxyglucose autoradiographic study in the rat. Brain Res 1991;538:289-94.
9. Redrobe JP, Bourin M. Partial role of 5-HT2 and 5-HT3 receptors in the activity of antidepressants in the mouse forced swimming test. Eur J Pharmacol 1997;325:129-35.
10. Redrobe JP, Pinot P, Bourin M. The effect of the potassium channel activator, cromakalim, on antidepressant drugs in the forced swimming test in mice. Fundam Clin Pharmacol 1996;10:524-8.
11. Nakagawa Y, Ishima T, Takashima T. The 5-HT3 receptor agonist attenuates the action of antidepressants in the forced swim test in rats. Brain Res 1998;786:189- 93.
12. Kos T, Popik P, Pietraszek M, Schafer D, Danysz W, Dravolina O, et al. Effect of 5-HT3 receptor antagonist MDL 72222 on behaviours induced by ketamine in rats and mice. Eur Neuropsychopharmacol 2006;6:297-10.
13. Bravo G, Maswood S. Acute treatment with 5-HT3 receptor antagonist, tropisetron, reduces immobility in intact female rats exposed to the forced swim test. Pharmacol Biochem Behav 2006;85:362-8.
14. Mahesh R, Perumal RV, Pandi PV. Microwave assisted synthesis of 2-(4-substituted piperazin-1-yl)-1, 8-naphthyridine-3-carbonitrile as a new class of serotonin 5-HT3 receptor antagonists. Bioorg Med Chem Lett 2004;14:5179-81.
15. Porsolt RD, Bertin A, Jalfre M. Behavioural despair in mice: A primary screening test for antidepressants. Arch Int Pharmacodyn Ther 1977;229:327-36.
16. Martin P, Massol J, Soubrie P, Puech AJ. Effects of triiodothyronine (T3) on the potentiation by antidepressants of L-5-hydroxytryptophan-induced head-twitches in mice. Prog Neuropsychopharmacol Biol Psychiatry 1989;13:735-48.
17. Costa E, Garatini S, Valzelli L. Interaction between reserpine, imipramine and chlorpromazine. Experientia 1960;16:461-3.
18. Song C, Leonard BE. The olfactory bulbectomized rat as a model of depression. Neurosci Biobehav Rev 2005;29:627-47.
19. Mahesh R, Devadoss T, Pandey DK, Yadav SK. Quinoxalin-2-carboxamides: Synthesis and pharmacological evaluation as serotonin type-3 (5-HT3) receptor antagonists. J Enzyme Inhib Med Chem 2011;26:610-5.
20. Boissier JR, Simon P. Action of caffeine on the spontaneous motility of the mouse. Arch Int Pharmacodyn Ther 1965;158:212-21.
21. Mahesh R, Rajkumar R, Minasri B, Perumal V. Potential antidepressants: Pharmacology of 2-(4-methyl piperazin-1-yl)-1, 8-naphthyridine-3-carbonitrile in rodent behavioural models. Pharmazie 2007;62:919-24.
22. Devadoss T, Pandey DK, Mahesh R, Yadav SK. Effect of acute and chronic treatment with QCF-3 (4-benzylpiperazin-1-yl) (quinoxalin-2-yl) methanone, a novel 5-HT3 receptor antagonist, in animal models of depression. Pharmacol Rep 2010;62:245-57.
23. Van Reizen H, Leonard BE. Effects of psychotropic drugs on the behaviour and neurochemistry of olfactory Bulbectomised rats. Pharmacol Ther 1990;47:21- 34.
24. Kelly JP, Wyrnn AS, Leonard BE. Olfactory bulbectomized rat as a model of depression: An update. Pharmacol Ther 1997;74:299-316.
25. Rajkumar R, Mahesh R, Borah M. Antidepressant- like effects of serotonin type- 3 antagonist, ondansetron: An investigation in behaviour-based rodent models. Behav Pharmacol 2008;19:29-40.
26. Ter Laak AM, Tsai RS, Donne-Op den Kelder GM, Carrupt PA, Testa B, Timmerman H. Lipophilicity and hydrogen-bonding capacity of H1-antihistaminic agents in relation to their central sedative side-effects. Eur J Pharm Sci 1994;2:373-84.
27. Millan MJ, Dekeyne A, Papp M, La Rochelle CD, MacSweeny C, Peglion JL, et al. S33005, a novel ligand at both serotonin and norepinephrine transporters: II. Behavioural profi le in comparison with venlafaxine, reboxetine, citalopram and clomipramine. J Pharmacol Exp Ther 2001;298:581-91.
28. Englert LF, Ho BT, Taylor D. The effects of (-) Δ9 -9-tetrahydrocannabinol on reserpine-induced hypothermia in rats. Br J Pharmacol 1973;49:243-52.
29. Bourin M, Fiocco AJ, Clenet F. How valuable are animal models in defi ning antidepressant activity? Hum Psychopharmacol 2001;16:9-21.
30. Lumia AR, Teicher MH, Salchli F, Ayers E, Possidente B. Olfactory bulbectomy as a model for agitated hyposerotonergic depression. Brain Res 1992;587:181- 5.
31. Blandina P, Goldfarb J, Walcott J, Green JP. Serotonergic modulation of the release of endogenous norepinephrine from rat hypothalamic slices. J Pharmacol Exp Ther 1991;256:341-7.
32. Schafer WR. How do antidepressants work? Prospect for genetic analysis of drug mechanism. Cell 1999;98:551-4.